Home

Revascularisation for Ischaemic Ventricular Dysfunction

A multicentre prospective randomised open controlled trial.

Aim: To evaluate the efficacy and safety of percutaneous coronary intervention compared to optimal medical therapy alone for ischaemic left ventricular dysfunction.

Primary Endpoint: All-cause death or hospitalisation due to heart failure

Secondary Endpoints:

• Quality of life score:
  • Kansas City Cardiomyopathy Questionnaire (KCCQ)
  • EuroQol EQ-5D-5L
• NYHA Functional Class
• LVEF on echocardiography at 6 months and 1 year
• Cardiovascular death, MI, CVA, major bleeding or unplanned revascularisation at 30 days
• Hospitalisation for heart failure
• Cardiovascular death
• Acute myocardial infarction
• Appropriate ICD therapy
• Unplanned further revascularisation
• Canadian Cardiovascular Society (CCS) class
• NHS resource use
• Brain natriuretic peptide (BNP or NT-Pro BNP) level
• Major bleeding